Epstein Secrets

andemic-damaged U.S. economy." The Dow ended the day 152.84 points higher at 28,363.66, the S&P 500 added 17.93 points to close at 3,453.49, and the Nasdaq climbed 21.31 points to 11,506.01. The AR (10/22, Choe, Troise, Veiga) and the Wall Street Journal (10/22, Bartholomew, Eisen, Subscription Publica

Vaccine Trial To Include Teens. USA Today (10/22, Weintraub, 10.31M) reports that "after months of testing its COVID-19 candidate vaccine in adults, Pfizer recently lowered the age of participation to 16, aiming to include at least 3,000 older teens." Pfizer is the "only one of the leading drug compani

37510 day earlier." The Dow posted a record, climbing 97.31 points to 34,230.34, and the S&P 500 gained 2.93 points to close at 4,167.59 while the Nasdaq fell 51.08 points to 13,582.42. Reuters <https://www.reuters.com/business/futures-rise-growth-stocks-bounce-economic-data-eyed-2021-05-05/> (5/5),

e House in the fight to end the pandemic." But "stocks of major pharmaceutical companies that have produced vaccines, including Modena, BioNTech and Pfizer, dropped sharply after news of the potential waivers first broke." Axios <https://www.axios.com/us-biden- vaccine-patents-waiver-65478c91-5107-41ff-

-off a day earlier." The Dow posted a record, climbing 97.31 points to 34,230.34, and the S&P 500 gained 2.93 points to close at 4,167.59 while the Nasdaq fell 51.08 points to 13,582.42. Reuters (5/5), flloomherg (5/5, Papuc, Barrett, 3.57M), and the Wall Street Journal (5/5, Ostroff, Subscription Pub

House in the fight to end the pandemic." But "stocks of major pharmaceutical companies that have produced vaccines, induding Moderna, BioNTech and Pfizer, dropped sharply after news of the potential waivers first broke." Axios (5/5, Baker, 1.26M) says a waiver "would open the door for foreign manufact

andemic-damaged U.S. economy." The Dow ended the day 152.84 points higher at 28,363.66, the S&P 500 added 17.93 points to close at 3,453.49, and the Nasdaq climbed 21.31 points to 11,506.01. The AP <https://www.usatoday.com/story/money/2020/10/22/us-stocks-flip-flop-amid-profit-reports-stimulus- talks/3

al-trials-pfizer- cincinnati/3709031001/> (10/22, Weintraub, 10.31M) reports that "after months of testing its COVID-19 candidate vaccine in adults, Pfizer recently lowered the age of participation to 16, aiming to include at least 3,000 older teens." Pfizer is the "only one of the leading drug companie

"optimism over the economy limited the day's declines." The Dow climbed 98.49 points to 33,171.37, the S&P 500 fell 3.45 points to 3,971.09 and the Nasdaq closed 79.08 points lower at 13,059.65. Bloomberg (3/29, Papuc, 3.57M) and the Wall Street Journal (3/29, Otani, Subscription Publication, 8.41M) p

been working beyond the drugmakers' initial experiments." The Minneapolis Star Tribune (3/29, Olson, 855K) says "clinical trials of the Moderna and Pfizer vaccines only looked at prevention of symptomatic infections, so the latest study of their effectiveness in health care and emergency medical worke

-off a day earlier." The Dow posted a record, climbing 97.31 points to 34,230.34, and the S&P 500 gained 2.93 points to close at 4,167.59 while the Nasdaq fell 51.08 points to 13,582.42. Reuters (5/5), Bloomberg (5/5, Papuc, Barrett, 3.57M), and the Wall Street Journal (5/5, Ostroff, Subscription Publ

House in the fight to end the pandemic." But "stocks of major pharmaceutical companies that have produced vaccines, including Modema, BioNTech and Pfizer, dropped sharply after news of the potential waivers first broke." Axios (5/5, Baker, 1.26M) says a waiver "would open the door for foreign manufac